Monitoring intraocular pressure (IOP) and optimizing targets. Diurnal IOP measurements Advances toward 24-hour measurements Considerations for IOP targets Importance of visual and structural tests Comorbidities When are aggressive targets appropriate?

Current and emerging treatment options for glaucoma. First-line therapies When are prostaglandins not the first choice? Selective laser trabeculotomy as a first-line option Adjunctive therapies with prostaglandin analogues Nitric oxide-delivering prostaglandin analogues Fixed-combination drugs vs. polypharmacy Drugs in clinical development Rho kinase inhibitors Adenosine A1 agonists Barriers to care Patient case(s)

By the end of the session the participant will be able to:

• Individualize intraocular pressure targets based on known risk factors and patient-specific characteristics, and optimize assessment of intraocular pressure profiles to readily identify peaks and fluctuations.
• Identify first-line pharmacotherapies, laser therapies, and glaucoma implants for lowering intraocular pressure, and select appropriate monotherapies and combination therapies for patients.
• Discuss present and emerging pharmacotherapies currently in clinical development and their mechanisms of action, and apply those therapies to patient cases.
• Describe barriers to care in the treatment of patients with glaucoma and what clinicians may do to aide patients in circumventing them.

ACCME Activity #201746223

ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.

Faculty Disclosure: Robert Chang, MD, Assistant Professor of Ophthalmology at the Stanford University Medical Center, Stanford, CA, discloses that he has received financial compensation as a consultant for Aerie and Ivantis. 

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant conflicts of interest to disclose.

Commercial Support Disclosure: This program is supported by an educational grant from Bausch & Lomb.

• Read the learning objectives above
• Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
• View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
• Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
• Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

*Required to view Printable PDF Version